The first evidence of treating IBD and SpA with the same cytokine-targeted therapy was with anti-TNFα, although randomized controlled trials with a pre-specified combined outcome were never realized, and there are very few interventional studies confirming the efficacy of both infliximab and adalimumab for treating articular disorders in IBD [79]. This evidence concerns the gene TNF and inflammatory bowel disease.